TICKERNERD
Menu
CTEVCTEVHealthcare · Health Information Services

CTEV Stock Forecast: Claritev Corp. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$37
+9.36% on the day

The 6 Wall Street analysts covering Claritev Corp. hold a median 12-month price target of $44 — +16.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 64 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$631.5M
Ticker Nerd rank
64 / 100
Median analyst target
$44
Analysts covering
6
Total return, dividends reinvested
1W
−2.2%
1M
+29.9%
YTD
−12.8%
1Y
−45.7%
From 52W high
−48.6%
From 52W low
+176.7%
$13
$73
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CTEV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Claritev Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
64 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
96
Accruals
87
Growth
76
Size
51
Quality
46
Issuance
38
Value
37
Momentum
33
Volatility
10

Revisions (96): Analysts have, on balance, been raising their forecasts.

Volatility (10): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CTEV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CTEV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Oct 25Jan 26Apr 26Jul 26CTEVHigh $73Median $44Low $28

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says6 analysts
5 Buy1 Hold0 Sell
Low $28Median $44High $73

The green dot is the last close — the median target sits +16.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
21 Aug 2026BarclaysMaintainsOverweight$28 → $40
12 Aug 2026Wells FargoMaintainsEqual-Weight$22 → $30
12 Aug 2026Wells FargoMaintainsEqual-Weight—
10 Aug 2026Canaccord GenuityMaintainsBuy$37 → $43
10 Aug 2026Canaccord GenuityMaintainsBuy—
10 Aug 2026CitigroupMaintainsBuy—
10 Aug 2026CitigroupMaintainsBuy$40 → $45
21 July 2026Canaccord GenuityMaintainsBuy$32 → $37
21 July 2026Canaccord GenuityMaintainsBuy—
29 May 2026Canaccord GenuityInitiatesBuy—
29 May 2026Canaccord GenuityInitiatesBuy$32
24 Apr 2026BarclaysInitiatesOverweight—
19 Mar 2026Wells FargoMaintainsEqual-Weight—
25 Feb 2026CitigroupMaintainsBuy—
24 Feb 2026GuggenheimMaintainsBuy—
24 Feb 2026Wells FargoMaintainsEqual-Weight—
9 Jan 2026CitigroupMaintainsBuy—
9 Jan 2026Wells FargoInitiatesEqual-Weight—
10 Nov 2025CitigroupMaintainsBuy—
22 Oct 2025CitigroupUpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CTEV appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CTEV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+5.8%
Analysts raising
1
Analysts cutting
0
Fundamentals

Claritev Corp. (CTEV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.2×

Cheaper than 85% of US stocks

Price / sales
0.6×

Cheaper than 79% of US stocks

Price / book
−2.2×

Cheaper than 96% of US stocks

EV / EBITDA
9.8×

Cheaper than 39% of US stocks

Growth & margins
Revenue growth (YoY)
6.6%

Higher than 43% of US stocks

Earnings growth (YoY)
6.6%

Higher than 43% of US stocks

Gross margin
67.3%

Higher than 80% of US stocks

Operating margin
12.8%

Higher than 69% of US stocks

Net margin
−28.5%

Higher than 13% of US stocks

Returns & dividend
Return on equity
170.1%

Higher than 98% of US stocks

Return on assets
1.2%

Higher than 52% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CTEV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
CTEVClaritev Corp.$631.5M
64
WEAVWeave Communications, Inc.$583.2M
79
SOPHSOPHiA GENETICS SA$712.0M
50
EVHEvolent Health, Inc.$529.2M
63
PHRPhreesia, Inc.$730.7M
59
NRCNRC Health$500.1M
87
HSTMHealthStream, Inc.$856.5M
94

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Claritev Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CTEV news & analysis

Marpai Expands Relationship with Claritev to Help Reduce Healthcare Costs for Employer Clients

Business Wire · 17 Aug 2026positive

Claritev announced that Marpai, Inc. has expanded its relationship with the company, bringing pre- and post-payment integrity capabilities to Marpai's administered health plans and claims. Marpai already uses Claritev's PHCS Network for access to healthcare providers and negotiated rates outside its clients' primary networks.

Why it matters — CTEV watchers would care because the expanded agreement deepens an existing customer relationship and broadens Claritev's role in Marpai's claims management operations.

Claritev Analysts Raise Their Forecasts Following Q2 Earnings

Benzinga · 10 Aug 2026positive

Claritev Corp (NYSE:CTEV) reported better-than-expected second-quarter financial results and raised its FY26 sales guidance above estimates. Analysts subsequently raised their forecasts following the earnings release.

Why it matters — The strong quarterly results and increased sales guidance signal improved company performance that a CTEV watcher would regard favorably.

Claritev Q2 Earnings Call Highlights

MarketBeat · 8 Aug 2026positive

Claritev (NYSE: CTEV) reported second-quarter revenue growth, record bookings and higher cash flow, leading the healthcare technology company to raise its full-year outlook for revenue, adjusted EBITDA and free cash flow.

Why it matters — CTEV watchers would care because the company raised its full-year guidance on revenue, adjusted EBITDA and free cash flow after a quarter of record bookings and higher cash flow.

Claritev Corporation (CTEV) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Seeking Alpha published the transcript of Claritev Corporation's (CTEV) Q2 2026 earnings call. The excerpt contains only the headline and source, indicating the transcript is available for review but provides no detailed content or financial figures.

Why it matters — A CTEV watcher would care because the Q2 2026 earnings call transcript offers insight into the company's recent performance and management commentary.

Claritev Corporation (CTEV) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 7 Aug 2026neutral

Claritev Corporation reported a second-quarter loss of $3.49 per share, narrower than the Zacks Consensus Estimate of a loss of $4.10, and topped revenue estimates. This compares with earnings of $0.32 per share in the same quarter a year ago.

Why it matters — A CTEV watcher would care because the loss came in better than consensus and revenue exceeded estimates, though the company swung to a loss from a profit a year earlier.

FAQ

Frequently asked questions about CTEV stock

What is the CTEV stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Claritev Corp. have a median 12-month price target of $44, with estimates ranging from $28 to $73. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CTEV stock a buy right now?

Of the 6 analysts covering Claritev Corp., 5 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Claritev Corp. 64 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CTEV?

As at 22 Aug 2026, Claritev Corp. ranks 64 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (96 of 100).

Will CTEV stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +16.7% from the last close, and Ticker Nerd's factor model ranks Claritev Corp. 64 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CTEV stock forecast for 2030?

No analyst covering Claritev Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CTEV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $28 to $73 over the next 12 months.

How has CTEV stock performed over the past year?

Claritev Corp. returned -45.7% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Claritev Corp. do?

Claritev Corporation is a distinguished entity in the realm of advanced technological solutions, predominantly serving the information technology and data analytics sectors. Its primary function revolves around providing cutting-edge analytical tools and platforms that enable businesses to harness the power of data-driven insights.

What is the latest news on CTEV?

The most recent item we track (Business Wire, 17 Aug 2026): "Marpai Expands Relationship with Claritev to Help Reduce Healthcare Costs for Employer Clients". Claritev announced that Marpai, Inc. has expanded its relationship with the company, bringing pre- and post-payment integrity capabilities to Marpai's administered health plans and claims. Marpai already uses Claritev's PHCS Network for access to healthcare providers and negotiated rates outside its clients' primary networks.

Company

About Claritev Corp.

Claritev Corporation is a distinguished entity in the realm of advanced technological solutions, predominantly serving the information technology and data analytics sectors. Its primary function revolves around providing cutting-edge analytical tools and platforms that enable businesses to harness the power of data-driven insights. Claritev Corporation is renowned for its innovative approach to big data integration, artificial intelligence, and cloud computing technologies, allowing companies across various industries such as finance, healthcare, and retail to enhance operational efficiency and strategic decision-making. The company is strategically significant in empowering enterprises to transform raw data into actionable intelligence, thereby helping them understand market trends and customer behavior with greater accuracy. Moreover, Claritev Corporation's relentless commitment to research and development places it at the forefront of technological advancements, contributing to its pivotal role in shaping the future of digital transformation. Claritev's solutions not only cater to large corporations but also to growing startups, enabling a diverse range of clients to achieve higher productivity and a competitive edge in the rapidly evolving market landscape.

CEO Mr. Travis S. Dalton · 3,000 employees · United States · https://www.claritev.com